| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCAT2 |
| Uniprot No | O15382 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-392aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMASSSFKAADLQLEMTQKPHKKPGPG EPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLF EGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLI EVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFP GGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQV LWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLL DMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILY KDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCAT2重组蛋白研究的示例参考文献(内容为模拟概括，仅供参考)：
---
1. **"Cloning and functional characterization of human mitochondrial branched-chain aminotransferase (BCAT2)"**
*Authors: Conway M.E., et al.*
**摘要**：该研究首次报道了人源BCAT2基因的克隆及重组蛋白在大肠杆菌中的表达，验证了其催化支链氨基酸转氨反应的活性，并分析了其与线粒体能量代谢的关联。
2. **"Structural insights into the substrate specificity of BCAT2 through recombinant protein mutagenesis"**
*Authors: Hutson S.M., et al.*
**摘要**：通过重组BCAT2蛋白的定点突变实验，揭示了酶活性中心的关键氨基酸残基对底物选择性的影响，为支链氨基酸代谢疾病的治疗提供理论依据。
3. **"Crystal structure of recombinant human BCAT2 in complex with a keto acid inhibitor"**
*Authors: Hull K.G., et al.*
**摘要**：利用X射线晶体学解析了重组BCAT2蛋白与酮酸抑制剂的复合物结构，阐明了其催化机制及潜在药物靶向位点。
4. **"BCAT2 overexpression reprograms glucose metabolism in cancer cells via recombinant protein-based assays"**
*Authors: Leone R.D., et al.*
**摘要**：通过重组BCAT2蛋白的功能实验，证明其过表达通过调控支链氨基酸代谢通路影响肿瘤细胞的葡萄糖利用，揭示了其在癌症代谢重编程中的作用。
---
*注：以上文献信息为示例性模拟，实际引用需以真实出版物为准。建议通过PubMed或Web of Science检索关键词“BCAT2 recombinant”获取最新研究。*
**Background of BCAT2 Recombinant Protein**
Branched-chain amino acid transaminase 2 (BCAT2) is a mitochondrial enzyme encoded by the *BCAT2* gene, playing a critical role in the metabolism of branched-chain amino acids (BCAAs: leucine, isoleucine, valine). It catalyzes the reversible transamination of BCAAs to their corresponding α-keto acids, linking amino acid catabolism to the tricarboxylic acid (TCA) cycle. BCAT2 is primarily expressed in peripheral tissues, such as the liver, skeletal muscle, and kidneys, where it regulates BCAA homeostasis and contributes to energy production, nitrogen shuttling, and gluconeogenesis.
Recombinant BCAT2 protein is engineered through molecular cloning and heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional enzyme for research applications. Its recombinant form retains catalytic activity, enabling studies on BCAA metabolism, enzyme kinetics, and interactions with substrates or inhibitors. BCAT2 has gained attention in metabolic disorders, cancer, and neurodegenerative diseases. For instance, dysregulated BCAA metabolism linked to BCAT2 activity is implicated in insulin resistance, obesity, and type 2 diabetes. In cancer, BCAT2 supports tumor growth by fueling the TCA cycle and promoting mTORC1 signaling via leucine-mediated activation.
Additionally, BCAT2’s role in neurotransmitter synthesis (e.g., glutamate) ties it to neurological conditions. Recombinant BCAT2 serves as a tool for drug discovery, structural analysis (e.g., X-ray crystallography), and elucidating metabolic adaptations in disease models. Challenges in studying endogenous BCAT2. such as tissue-specific isoforms and post-translational modifications, highlight the utility of recombinant protein in controlled experimental settings. Ongoing research aims to explore BCAT2 as a therapeutic target or biomarker in metabolic and oncological contexts.
×
